培瑞克的争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 2 条
2019
Perrigo在全球召回雷尼替丁产品
宣布召回
Perrigo Company plc宣布在全球零售客户层面自愿召回雷尼替丁，原因是产品可能含有NDMA杂质。
来源摘录
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes). The recall is being taken due to possible presence of a nitrosamine impurity called N-nitrosodimethylamine (NDMA).
Company Announcement Date: October 23, 2019
This recall has been completed and FDA has terminated this recall.
2018
爱尔兰资本利得税争议
爱尔兰税务专员声称Perrigo欠约16.4亿欧元的资本利得税，与Elan早前将Tysabri出售给Biogen有关。Perrigo对交易分类提出异议，并主张应作为贸易收入处理。该争议发生在Perrigo 2013年爱尔兰税负倒置之后，导致公司股价单日大幅下跌。